Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MPDL3280A in locally advanced or metastatic urothelial bladder cancer
2013-005486-39Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Roche. Primary endpoint: Objective response rate. Started Jun 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2013-005486-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005486-39.